ArrePath, a Princeton, New Jersey-based anti-infective drug discovery company addressing the global health challenge of drug-resistant infections, announced today that it raised $20 million in seed financing to advance its proprietary, machine learning (ML)-based platform for the discovery of new classes of anti-infectives to overcome antimicrobial resistance (AMR).
The Boehringer Ingelheim Venture Fund, Insight Partners, and Innospark Ventures co-led the financing, which also included Viva BioInnovator, Arimed Capital, PTX Capital, and Nor’easter Ventures.
ArrePath also announced that Dr. Lloyd Payne has been named President and CEO.
Company: ArrePath
Raised: $20.0M
Round: Seed Round
Funding Month: March 2022
Lead Investors: Boehringer Ingelheim Venture Fund, Insight Partners, and Innospark Ventures
Additional Investors: Viva BioInnovator, Arimed Capital, PTX Capital, and Nor’easter Ventures
Company Website: https://arrepath.com/
Software Category: Machine learning (ML) and imaging-based drug discovery platform
About the Company: ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state-of-the-art technologies and novel strategies. ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug-resistant infections. The company’s proprietary machine learning (ML)-based platform enables the rapid and efficient identification of anti-infective agents with new mechanisms of action at the outset of the discovery process, through a deep understanding and analysis of pathogen behavior. ArrePath’s approach leverages a novel technology platform to enable the discovery and development of new and differentiated antibiotics by decoding the complex behavior of bacteria when exposed to new chemical entities (known as ‘bacterial autopsies’), leading to the efficient elucidation of biological mechanisms of action. The platform’s proof-of-concept has been demonstrated in studies published in Cell by ArrePath’s scientific founder, Zemer Gitai, Ph.D., Edwin Grant Conklin Professor of Biology at Princeton University.
Source: https://www.businesswire.com/news/home/20220303005116/en/ArrePath-Announces-20-Million-Seed-Financing-to-Advance-its-Machine-Learning-based-Platform-for-Discovery-of-Novel-Anti-infectives-Addressing-Antimicrobial-Resistance